Aktie A3DKFH DIFFUSION PHARMA
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Diffusion Pharma

Aktien

A3DKFH

US2537484048

DFFN

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Diffusion Pharma : CervoMed Corporate Presentation December 2023
Diffusion Pharmaceuticals Inc.(NasdaqCM:DFFN) dropped from NASDAQ Composite Index
CervoMed Completes Merger with EIP Pharma
EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. in a reverse merger transaction.
Diffusion Pharmaceuticals Shareholders Approve Merger With EIP Pharma; Shares Rise
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Diffusion Pharmaceuticals : EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies - Form 8-K
Diffusion Pharmaceuticals : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION - Form 8-K
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Diffusion Pharmaceuticals : EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference - Form 8-K
Diffusion Pharmaceuticals Inc. Appoints Jill Davidson as A Director of the Company, Effective July 26, 2023
DIFFUSION PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO
DIFFUSION PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Diffusion Pharmaceuticals : EIP Pharma to Present at JMP Securities Life Sciences Conference - Form 8-K
Top Premarket Gainers
DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN
Diffusion Pharmaceuticals, EIP Pharma Agree to Merge to Create New Combined Entity
DIFFUSION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DKFH Aktie
  4. Nachrichten Diffusion Pharma
  5. Andere Sprachen